Last reviewed · How we verify
AI assisted insulin system
An artificial intelligence-assisted system that optimizes insulin dosing and delivery by analyzing real-time glucose data and patient factors to improve glycemic control.
An artificial intelligence-assisted system that optimizes insulin dosing and delivery by analyzing real-time glucose data and patient factors to improve glycemic control in diabetes management. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | AI assisted insulin system |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This system uses machine learning algorithms to process continuous glucose monitoring data, patient behavior patterns, and physiological parameters to provide personalized insulin dosing recommendations. It aims to reduce hypoglycemic episodes and improve overall glucose management by predicting glucose trends and adjusting insulin delivery accordingly, functioning as a decision-support tool for insulin therapy optimization.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus requiring insulin therapy
Common side effects
- Hypoglycemia
- Hyperglycemia
- Device malfunction or software error
Key clinical trials
- Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol (NA)
- Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards (NA)
- Explainable Insulin Decision-making System to Assist Physicians in Diabetes Management
- Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients (NA)
- Efficacy of Using Large Language Model to Assist in Diabetic Retinopathy Detection (NA)
- AI-Assisted Insulin Titration System on Inpatients Glucose Control (NA)
- Artificial Intelligence Assisted Insulin Titration System (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AI assisted insulin system CI brief — competitive landscape report
- AI assisted insulin system updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI